Serum S-100B protein in the diagnosis of cerebral radiation injuries in patients with brain malignant tumor: a preliminary study

Abstract

Objective To study the value of serum S-100B protein in the diagnosis of cerebral radi-ation injuries in patients with brain malignant tumor. Methods Serum S-100B protein level was deteetod by enzyme-linked immunosorbent assay in 56 patients with brain malignant tumor before, during and after radio-therapy. Effects of dose and method of radiotherapy, peritumoral edema degree and Karnofsky performance status on serum S-100B level were studied. Results The levels of serum S-100B protein in the patients be-fore radiotherapy and control group were 0. 039μg/L and 0.044 μg/L ( t = 1.48 ,P =0. 186). The levels of serum S-100B protein before, in the middle of (30-40 Gy) and after (60 -70 Gy) radiotherapy were 0.044 μ/L, 0.049 μ/L and 0.079 μg/L, respectively ( F = 67.26, P = 0.000). The differences after ra-diotherapy were also significant among patients with three methods of radiotherapy (F = 20.32, P = 0.000), different degree of pefitumoral edema ( F = 12.94, P =0. 000 ) and Karnofsky perforrnanee status ( t = 2.71, P =0.007). Conclusions High level of serum S-100B protein is associated with cerebral radiation injuries in patients with brain malignant tumor, which is influenced by the dose and method of radiotherapy, Karnof-sky performance stares and degree of peritumoral edema. High level of serum S-100B protein may serve as an early predictor of cerebral radiation injury. Key words: Brain neoplasms/radiotherapy; Cerebral, radiation injuries; S-100B protein; Enzyme-linked immunosorbent assay